Navigation Links
Shire plc Appoints Two New Board Directors

DUBLIN, June 17, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Dr David Ginsburg and Ms Anne Minto OBE, have been appointed to the Shire Board of Directors with immediate effect.

Dr Ginsburg, MD is currently Professor of Internal Medicine & Human Genetics at the Life Sciences Institute, University of Michigan; an Investigator at the Howard Hughes Medical Institute and the Warner-Lambert/Parke-Davis Professor of Medicine.

Dr Ginsburg qualified at Yale University and has a very distinguished background that includes many research achievements, fellowships, awards and published papers. These have included a research post at Harvard Medical School and numerous senior professorial positions across a broad spectrum of medical specializms at the University of Michigan. Dr Ginsburg has also been appointed to Shire's Science & Technology Committee.

Anne Minto is Group Director Human Resources at Centrica plc, a FTSE 30 integrated energy company operating in the UK and US. Ms Minto qualified as a lawyer at Aberdeen University and has an impressive business career that includes senior roles at Shell UK and Smiths Group plc and the position of deputy director-general of the Engineering Employers' Federation.

Ms Minto is a Fellow of both the Chartered Institute of Personnel & Development and the London City and Guilds and a Member of Law Society of Scotland. Anne Minto has also been appointed to Shire's Remuneration Committee and she will assume the Chair of that Committee on the retirement of Kate Nealon from the Shire Board at the end of Ms Nealon's term of office at the end of July.

Shire Chairman, Matthew Emmens commented: "I am very pleased that we have attracted two highly qualified and experienced Directors to our Board. David's medical background and areas of specializm and Anne's legal, commercial and remuneration experience will be welcome additions to our strong team. I'd like to thank Kate Nealon for her four years of service to Shire's Board and for her contributions to the Remuneration Committee."

There is no further information that is required to be disclosed under 9.6.13R of the United Kingdom listing rules

Notes to editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:


Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor Relations
    Clea Rosenfeld (Rest of the World)

    Eric Rojas (North America)


    Jessica Mann (Rest of the World)

    Matthew Cabrey (North America, Specialty Pharma)

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
(Date:10/9/2015)... ROCKVILLE, Md. , Oct. 9, 2015 ... company developing next generation vaccines based on the ... into an exclusive worldwide licensing agreement with Astellas ... or prevention of any and all allergic diseases ... Therapeutics will receive an upfront payment of $300 ...
(Date:10/8/2015)... UK (PRWEB) , ... October 08, 2015 , ... Researchers ... literally see inside the living brain, providing a new tool to study how diseases ... is reported by Woo June Choi and Ruikang Wang of the UW Department of ...
(Date:10/8/2015)... Pa. , Oct. 8, 2015  Clarkston Consulting, ... the call for applications for the 2016 Clarkston Scholars ... a life sciences related field of study, a $10,000 ... selected Clarkston Scholar will receive exposure to the life ... in Pennsylvania Bio events over the course of the ...
(Date:10/8/2015)... , Oct. 8, 2015  Today, DuPont and ... for genome editing, jointly announced a strategic alliance. ... cross-licensed their respective patent portfolios, with DuPont receiving ... in major row crops, and non-exclusive rights in ... --> --> In ...
Breaking Biology Technology:
... Gretel ventured into the forest, they left a trail ... world, cellular phones, Global Positioning System (GPS), WiFi, and ... friends, family, and colleagues while helping us find our ... ubiquity of such devices, with few exceptions, today,s firefighters ...
... Kendle (Nasdaq: KNDL ), a leading, ... of its senior clinical development experts will present ... Association (DIA) 47th Annual Meeting, June 19-23, 2011, ... including the benefits of hybrid monitoring; finding an ...
... New Generation of the Ziehm Vision RFD Offers,Lower-Cost ... has launched a new generation of the Ziehm Vision,RFD mobile ... it to be used over an almost unlimited period,of time, ... to its mobility and significantly lower investment costs,the Ziehm Vision ...
Cached Biology Technology:
(Date:9/30/2015)... Sept. 30, 2015  With nearly 300,000 Americans living ... new SCIs estimated to reach 12,500 annually, the role ... Resource Services for Independent Living (SCRS-IL) is increasingly ... California opening doors to independence for ... and services, notably assistive technology services and education. ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... Sept. 28, 2015  The monitoring of vital ... body temperature, is an essential component of patient ... of deterioration in a patient,s condition. However, in ... are typically taken during routine observation rounds only ... patient deteriorates between these observation rounds, the warning ...
Breaking Biology News(10 mins):
... VTT Technical Research Centre of Finland indicates that there is ... sold in Finland as regards fuel consumption in normal driving. ... using six used cars of different make under laboratory conditions. ... fuel consumption is significantly higher with 95E10 petrol than with ...
... A group of scientists at the Instituto Gulbenkian de Cincia, ... skeleton and organ size. The team, led by Florence Janody, ... the proteins that regulates the skeleton of the cell also ... and proliferation. Their findings have implications for cancer research, as ...
... organ in the human body that metabolizes foreign compounds such ... liver as an alarm system, researchers are starting to better ... their effects on the human body. One ... the Virginia Tech Institute of Critical Technology and Applied Science,s ...
Cached Biology News:
Rabbit polyclonal to Olfactory Receptor LS189744 ( Abpromise for all tested applications)....
Recognizes the VZV nucleocapsid by indirect immunofluorescence and immunoprecipitation. Shows cross-reactivity to HSV....
Mouse monoclonal [11C9] to Zeralenone ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to BSA: Zeralenone...
AK6 Antibody...
Biology Products: